<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">Regarding 2
 <sup>nd</sup> generation NAs, entecavir has been rarely associated with clinical signs of mitochondrial damage, such as lactic acidosis and mostly in patients with decompensated cirrhosis or receiving a combination treatment. Cohort studies and clinical trials failed to detect an increased risk of lactic acidosis in entecavir recipients
 <sup>
  <xref ref-type="bibr" rid="CR30">30</xref>
 </sup>. Furthermore, to our knowledge, tenofovir has never been associated with lactic acidosis in HBV-infected patients.
</p>
